Andreas Hochhaus

2 weeks ago | nature.com | Andreas Hochhaus |Dong-Wook Kim |Jorge Cortés |Koji Sasaki |Michael J. Mauro |Timothy Hughes | +7 more

AbstractAsciminib is the first approved BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP). The present final analysis of the phase 1, open-label, nonrandomized trial (NCT02081378) assessed the long-term safety, tolerability, and antileukemic activity of asciminib in 115 patients with chronic myeloid leukemia in chronic phase without the BCR::ABL1T315I mutation who received asciminib 10–200 mg twice daily (BID) or 80–200 mg once daily (cutoff: March 14, 2023).

1 month ago | nature.com | Kirsi Manz |Florian H. Heidel |Steffen Koschmieder |Frank Stegelmann |Andreas Hochhaus |Haifa Kathrin Al-Ali | +3 more

AbstractMyeloproliferative neoplasms (MPN) are associated with a variety of symptoms that severely impact patients’ quality of life and ability to perform daily activities. Recent studies showed differences in the perception of physician- versus patient-reported symptom burden. However, studies directly comparing patient- and physician-reported ratings are lacking.

Sep 2, 2024 | nature.com | Elias Jabbour |Jane F. Apperley |Jorge Cortés |Michael Deininger |Elisabetta Abruzzese |Daniel DeAngelo | +2 more

Correction to: Leukemia https://doi.org/10.1038/s41375-024-02159-0, published online 29 January 2024Following publication of the article, the authors realized that several data points in Figure S3B and the accompanying manuscript text were incorrect. This oversight has been addressed and the corrected figure has been added. 1.

May 16, 2024 | nature.com | Jorge Cortés |Koji Sasaki |Timothy Hughes |Michael J. Mauro |Andreas Hochhaus |Michael C. Heinrich | +5 more

AbstractAsciminib targets the BCR::ABL1 myristoyl pocket, maintaining activity against BCR::ABL1T315I, which is resistant to most approved adenosine triphosphate–competitive tyrosine kinase inhibitors. We report updated phase I results (NCT02081378) assessing safety/tolerability and antileukemic activity of asciminib monotherapy 200 mg twice daily in 48 heavily pretreated patients with T315I-mutated chronic-phase chronic myeloid leukemia (CML-CP; data cutoff: January 6, 2021).

Jan 29, 2024 | nature.com | Elias Jabbour |Jane F. Apperley |Jorge Cortés |Michael Deininger |Elisabetta Abruzzese |Daniel DeAngelo | +2 more

AbstractPonatinib, the only approved all known-BCR::ABL1 inhibitor, is a third-generation tyrosine-kinase inhibitor (TKI) designed to inhibit BCR::ABL1 with or without any single resistance mutation, including T315I, and induced robust and durable responses at 45 mg/day in patients with CP-CML resistant to second-generation TKIs in the PACE trial.